Chapter 1: Executive summary

• 1.1 Market scope and segmentation
• 1.2 Key questions answered in this study
• 1.3 Executive summary - I
• 1.4 Executive summary - II

Chapter 2: Market overview

• 2.1. Market definitions
• 2.2. The U.S. market overview – by revenue

- The U.S. historical (2015-2017) market revenue (USD Bn)

- The U.S. forecasted (2018-2023) market revenue (USD Bn)

• 2.3. The U.S. market overview – by volume

- The U.S. historical (2015-2017) market volume (Million units)

- The U.S. forecasted (2018-2023) market volume (Million units)

• 2.4. The U.S. market drivers and challenges
  • 2.4.1. The U.S. market drivers
  • 2.4.2. The U.S. market challenges
• 2.5. The U.S. market trends
• 2.6. Value chain

Chapter 3: The U.S. major segment overview - by disease indication

• 3.1. Disease indication: Pneumococcal, Hib - by revenue, by volume, CAGR

- Overview - by disease indication

- Market share (2015, 2018 & 2023): Pneumococcal – The U.S. (USD Bn, Million units)

- Market share (2015, 2018 & 2023): Hib – The U.S. (USD Bn, Million units)

• 3.2. Disease indication: DTP, Meningococcal - by revenue, by volume, CAGR

- Overview - by disease indication

- Market share (2015, 2018 & 2023): DTP – The U.S. (USD Bn, Million units)

- Market share (2015, 2018 & 2023): Meningococcal – The U.S. (USD Bn, Million units)

Chapter 4: The U.S. major segment overview - by end user

• 4.1. End user: Pediatric, Adult - by revenue, by volume, CAGR

- Overview - by end user

- Market share (2015, 2018 & 2023): Paediatric – The U.S. (USD Bn, Million units)

- Market share (2015, 2018 & 2023): Adult – The U.S. (USD Bn, Million units)

Chapter 5: Competitive landscape

• 5.1. Company market share

- Top 5 companies

• 5.2. Company overview - GlaxoSmithKline

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

• 5.2(A) Executive profile – GlaxoSmithKline
• 5.3. Company overview – Pfizer Inc.

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

• 5.3(A) Executive profile - Pfizer Inc.
• 5.4. Company overview – Merck & Co.

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

• 5.4(A) Executive profile - Merck & Co.
• 5.5. Company overview – Novartis

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

• 5.5(A) Executive profile - Novartis
• 5.6. Company overview – Sanofi Pasteur

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

• 5.6(A) Executive profile - Sanofi Pasteur
• 5.7. Company overview – CSL Limited

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

• 5.7(A) Executive profile - CSL Limited
• 5.8. Company overview – Nuron Biotech Inc.

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

• 5.8(A) Executive profile – Nuron Biotech Inc.

Appendix

- List of tables

- Assumptions

- Conclusion

- Research methodology

- About Netscribes Inc.

Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research

The U.S. Conjugate Vaccine Market:

The Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. The U.S. is one of the prominent markets for conjugate vaccines.

Scheduled vaccination of conjugate vaccines has eradicated health disparities and consequently, the rate of incidence of diseases in the U.S. have been lower. Native Alaskan/American Indian and African-American children had much higher rates of invasive pneumococcal diseases than white children in the U.S. Vaccination has wiped out these health disparities, and the incidence of these diseases is now relatively low across all groups.

Market Segmentation:

o Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others. The highest penetration among paediatrics is that of DTP vaccines.
o Based on end user, the market is segmented into pediatric and adult.

Key growth factors:

The U.S. is projected to be one of the most significant markets for conjugate vaccines during the forecast period, due to a rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. Increased diagnosis and treatments would fuel the conjugate vaccines market. Recommended vaccines and dosages are updated on a regular basis to comply with prevalent serogroups of infectious agents. For example, the CDC has its own immunization schedule for U.S. citizens. This has increased the effectiveness of administered vaccines, which thereby boosts the demand for the product, leading to increase in market sales. Growing initiatives by HHS to reduce infectious diseases by increasing immunization rates and immunization recommendations will fuel the growth of the market. For instance, the Healthy People 2020 aims for immunization to prevent and treat infectious diseases.

Threats and key players:

o The U.S. conjugate vaccine market is expected to grow positively. But since it is a saturated market, the scope for significant growth is limited. In North America, the population above 65 years of age has decreased from the year 2014 to 2016. So, the demand for adult vaccines has also lowered. The overall penetration rates for the adult segment, is lower than that of the pediatric segment.
o Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

What’s covered in the report?

1. Overview of the U.S. conjugate vaccine market
2. Market drivers and challenges in the U.S. conjugate vaccine market
3. Market trends in the U.S. conjugate vaccine market
4. Historical, current and forecasted market size data for the U.S. based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for the U.S. based on the end user (paediatric and adult conjugate vaccines) – by revenue and by volume
6. Analysis of the competitive landscape and profiles of major companies operating in the U.S. market

Why buy?

o Understand the demand for conjugate vaccines to determine the viability of the market
o Develop strategies based on the drivers and trends for each of the segments
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
o Recognize the key competitors of this market and respond accordingly
o Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
o Define the competitive positioning by comparing the products and services with the key players in the market

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.